Prnewswireยท2025-08-27 11:15Core Insights - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will participate in the Cantor Global Healthcare Conference 2025 on September 3, 2025 [1] - The company is focused on transforming treatment for patients with its portfolio, including ZYNLONTA and a next-generation PSMA-targeting ADC [3][4] Company Overview - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [5] - The company specializes in ADC development, encompassing clinical, manufacturing, and commercialization capabilities [5] Product Development - ZYNLONTA, an ADC directed at CD19, has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4] - The company is also developing a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker [4]